Outputs (15)

Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) (2021)
Journal Article
Barajas, R. F., Politi, L. S., Anzalone, N., Schöder, H., Fox, C. P., Boxerman, J. L., Kaufmann, T. J., Quarles, C. C., Ellingson, B. M., Auer, D., Andronesi, O. C., Ferreri, A. J. M., Mrugala, M. M., Grommes, C., Neuwelt, E. A., Ambady, P., Rubenstein, J. L., Illerhaus, G., Nagane, M., Batchelor, T. T., & Hu, L. S. (2021). Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-Oncology, 23(7), 1056-1071. https://doi.org/10.1093/neuonc/noab020

Advanced molecular and pathophysiologic characterization of primary central nervous system lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, staging, an... Read More about Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP (2021)
Journal Article
Eyre, T. A., Wilson, W., Kirkwood, A. A., Wolf, J., Hildyard, C., Plaschkes, H., Griffith, J., Fields, P., Gunawan, A., Oliver, R., Booth, S., Kothari, J., Fox, C. P., Martinez-Calle, N., McMillan, A., Bishton, M., Collins, G. P., & Hatton, C. S. R. (2021). Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. Blood Advances, 5(8), 2229-2236. https://doi.org/10.1182/bloodadvances.2021004286

Infection-related morbidity and mortality are increased in older patients with diffuse large B-cell lymphoma (DLBCL) compared with population-matched controls. Key predictive factors for infection-related hospitalization during treatment with rituxim... Read More about Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.

Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients — A British Society for Haematology Guideline (2021)
Journal Article
Shah, N., Eyre, T. A., Tucker, D., Kassam, S., Parmar, J., Featherstone, C., Andrews, P., Asgari, E., Chaganti, S., Menne, T. F., Fox, C. P., Pettit, S., Suddle, A., Bowles, K. M., & Haemato‐Oncology Task Force of the British Society for Haematology and the British Transplantation Society. (2021). Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients — A British Society for Haematology Guideline. British Journal of Haematology, 193(4), 727-740. https://doi.org/10.1111/bjh.17421

MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial (2021)
Journal Article
Ferreri, A. J. M., Doorduijn, J. K., Re, A., Cabras, M. G., Smith, J., Ilariucci, F., Luppi, M., Calimeri, T., Cattaneo, C., Khwaja, J., Botto, B., Cellini, C., Nassi, L., Linton, K., McKay, P., Olivieri, J., Patti, C., Re, F., Fanni, A., Singh, V., …International Extranodal Lymphoma Study Group (IELSG), I. E. L. S. G. (. (2021). MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematology, 8(2), e110-e121. https://doi.org/10.1016/S2352-3026%2820%2930366-5

Background: Secondary CNS lymphoma is a rare but potentially lethal event in patients with diffuse large B-cell lymphoma. We aimed to assess the activity and safety of an intensive, CNS-directed chemoimmunotherapy consolidated by autologous haematopo... Read More about MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.

A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies (2021)
Journal Article
Collins, G. P., Clevenger, T. N., Burke, K. A., Yang, B., MacDonald, A., Cunningham, D., Fox, C. P., Goy, A., Gribben, J., Nowakowski, G. S., Roschewski, M., Vose, J. M., Vallurupalli, A., Cheung, J., Raymond, A., Nuttall, B., Stetson, D., Dougherty, B. A., Schalkwijk, S., Carnevalli, L. S., …Flinn, I. (2021). A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. Leukemia & Lymphoma, 62(11), 2625-2636. https://doi.org/10.1080/10428194.2021.1938027

In a phase 1b study of acalabrutinib (a covalent Bruton tyrosine kinase (BTK) inhibitor) in combination with vistusertib (a dual mTORC1/2 inhibitor) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), multiple ascending doses... Read More about A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.